New targeted therapies reshape biliary tract cancer care, highlighting FGFR2/IDH1, HER2 and KRAS options plus smarter ...
Scientists at Pitt developed BiliSeq in 2019, a molecular test that detects both DNA and RNA sequences in biopsy samples to ...
If you or a loved one has gallbladder or bile duct cancer, you may be interested in learning more about treatments for it. For a long time, the standard treatment options for this cancer type were ...
Please provide your email address to receive an email when new articles are posted on . The FDA granted accelerated approval to zanidatamab-hrii for treatment of adults with previously treated ...
Hosted on MSN
Bile duct cancer: These changes occur in the body at the onset of bile duct cancer; early diagnosis can save lives
Cancer is a disease that can be treated more effectively if diagnosed early. However, some types of cancer have mild early symptoms and mimic common health problems. Therefore, the disease is often ...
Bile duct cancer is classified by location: intrahepatic, perihilar, or distal, influencing symptoms and treatment options. Diagnosis involves blood tests, imaging, endoscopic procedures, and biopsy ...
The PATHWAY HER2 (4B5) test helps to identify patients with previously-treated, unresectable or metastatic HER2-positive biliary tract cancer (BTC) who may be eligible for treatment with ZIIHERA.
Ateganosine combined with Libtayo shows improved progression-free survival in advanced non-small cell lung cancer, suggesting potential long-term use. Spevatamig, a bispecific antibody, is being ...
Biliary Tract Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 10.1% During the Forecast Period (2025-2034) | DelveInsight LAS VEGAS, March 2, 2026 /PRNewswire/ -- The biliary ...
Hosted on MSN
I didn't have any symptoms… Hard-to-detect bile duct cancer, only 30% of surgery is possible
The bile duct is a pathway in which bile produced in the liver travels through the gallbladder to the duodenum, and a malignant tumor in the bile duct is called 'bile duct cancer'. Bile duct cancer is ...
Zanidatamab-hrii received FDA accelerated approval for HER2-positive biliary tract cancer, showing a 52% objective response rate in the HERIZON-BTC-01 trial. Biliary tract cancers represent 3% of ...
Biliary Tract Cancer Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results